HC Wainwright Reiterates Buy Rating for Poseida Therapeutics (NASDAQ:PSTX)

HC Wainwright reiterated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Poseida Therapeutics Stock Up 9.4 %

PSTX stock opened at $3.95 on Thursday. Poseida Therapeutics has a twelve month low of $1.60 and a twelve month high of $4.27. The company has a quick ratio of 2.56, a current ratio of 2.56 and a debt-to-equity ratio of 0.69. The firm has a market cap of $382.99 million, a PE ratio of -3.32 and a beta of 0.53. The business has a 50 day moving average of $2.98 and a 200 day moving average of $3.05.

Poseida Therapeutics (NASDAQ:PSTX) last issued its earnings results on Tuesday, May 14th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.18. Poseida Therapeutics had a negative return on equity of 97.36% and a negative net margin of 131.95%. The business had revenue of $28.14 million for the quarter, compared to the consensus estimate of $11.25 million. On average, research analysts forecast that Poseida Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Poseida Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Bayesian Capital Management LP purchased a new position in shares of Poseida Therapeutics in the 1st quarter worth $33,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Poseida Therapeutics in the 4th quarter worth $36,000. Tower Research Capital LLC TRC boosted its stake in shares of Poseida Therapeutics by 110.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock worth $36,000 after buying an additional 5,606 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Poseida Therapeutics in the 4th quarter worth $76,000. Finally, Lazard Asset Management LLC boosted its stake in shares of Poseida Therapeutics by 280.3% in the 1st quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after buying an additional 21,138 shares during the last quarter. 46.87% of the stock is currently owned by hedge funds and other institutional investors.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.